TYNADOTE

Phase 2Small molecule

SSinew Pharma Inc.

TYNADOTE is one of 16 small molecule programs targeting Overdose. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverdoseActive, not recruiting

OverdosePhase 2

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Overdose

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Suboxone

Haldol

1 4

Ativan

BBausch Health Americas, Inc.

Phase 2

1 5

Cysteine Hydrochloride

Novartis

Phase 1

1 6

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 1

1 7

Naloxone Intranasal

NNorwegian University of Science and Technology

Phase 3

1 8

Sublocade

IIndivior Inc.

Phase 3

1 9

Intravenous

IIsfahan University of Medical Sciences

Phase 2

1 10

MS Contin

Merck & Co.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Overdose

NCT05557448

Clinical

Trials by Indication[1]

Overdose1 trial

To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

Recruiting·SSinew Pharma Inc.·Phase 2·NCT05557448·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TYNADOTE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TYNADOTE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TYNADOTE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinew Pharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSinew Pharma Inc.

TYNADOTE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Overdose1 trial

References

Drug Info

Quick Facts

Related News